Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Ditropan XL once-daily oxybutynin: Phase III; NDA submitted

Results from a double-blind Phase III trial comparing Ditropan XL with

Read the full 118 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE